The estimated Net Worth of Michael Joseph Golembiewski is at least $17.3 Tausend dollars as of 30 November 2023. Mr Golembiewski owns over 83,000 units of Seelos Therapeutics stock worth over $17,290 and over the last 9 years he sold SEEL stock worth over $0.
Mr has made over 1 trades of the Seelos Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 83,000 units of SEEL stock worth $100,430 on 30 November 2023.
The largest trade he's ever made was buying 83,000 units of Seelos Therapeutics stock on 30 November 2023 worth over $100,430. On average, Mr trades about 8,300 units every 0 days since 2016. As of 30 November 2023 he still owns at least 86,450 units of Seelos Therapeutics stock.
You can see the complete history of Mr Golembiewski stock trades at the bottom of the page.
Michael J. Golembiewski is the Chief Financial Officer at Seelos Therapeutics.
Mr Golembiewski is 49, he's been the Chief Financial Officer of Seelos Therapeutics since . There are 4 older and no younger executives at Seelos Therapeutics. The oldest executive at Seelos Therapeutics, Inc. is Dr. Raj Mehra J.D., Ph.D., 61, who is the Founder, Chairman, CEO & Pres.
Michael's mailing address filed with the SEC is C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 2ND FLOOR, NEW YORK, NY, 10022.
Over the last 6 years, insiders at Seelos Therapeutics have traded over $0 worth of Seelos Therapeutics stock and bought 409,757 units worth $387,856 . The most active insiders traders include Brian Lian, Raj Mehra und Robin L Smith. On average, Seelos Therapeutics executives and independent directors trade stock every 231 days with the average trade being worth of $13,659. The most recent stock trade was executed by Raj Mehra on 1 December 2023, trading 75,757 units of SEEL stock currently worth $99,999.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Seelos Therapeutics executives and other stock owners filed with the SEC include: